Matches in Wikidata for { <http://www.wikidata.org/entity/Q90026109> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q90026109 description "2019 թվականի հուլիսի 10-ին հրատարակված գիտական հոդված" @default.
- Q90026109 description "article scientifique publié en 2019" @default.
- Q90026109 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q90026109 description "scientific article published on 10 July 2019" @default.
- Q90026109 description "wetenschappelijk artikel" @default.
- Q90026109 description "наукова стаття, опублікована 10 липня 2019" @default.
- Q90026109 name "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 name "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 type Item @default.
- Q90026109 label "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 label "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 prefLabel "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 prefLabel "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 P1433 Q90026109-A73B3648-665F-4607-A5C0-5112C05E09DC @default.
- Q90026109 P1476 Q90026109-BB743263-6DD6-491D-A69B-CC3256938B87 @default.
- Q90026109 P2093 Q90026109-632502F1-55BD-4D70-90FB-761110F1D531 @default.
- Q90026109 P2093 Q90026109-F23CC0E0-717C-4164-B144-FF8C1EDF771E @default.
- Q90026109 P2507 Q90026109-980A24A4-A55C-46DE-A3F5-76AD0B6F3FA0 @default.
- Q90026109 P31 Q90026109-0DE4221A-DECB-4DB9-8908-445A7EC09F66 @default.
- Q90026109 P356 Q90026109-CD8015A0-43FB-4D3C-8E0D-F2F6C2BC7587 @default.
- Q90026109 P577 Q90026109-4A19DF3E-2412-457E-94A6-916AA2ADD118 @default.
- Q90026109 P698 Q90026109-CB1DB2EC-3CA9-4EEA-9D58-3D6AAD7C3DFF @default.
- Q90026109 P921 Q90026109-21EEAC6F-C1EB-44FB-A640-4DD71F7F5528 @default.
- Q90026109 P921 Q90026109-2D518D53-165F-493C-9A10-5C528AD2CF25 @default.
- Q90026109 P921 Q90026109-B0C9D543-E9EC-4332-AF5D-DA12E60465D2 @default.
- Q90026109 P921 Q90026109-E14694A8-8B37-4972-A828-9C91FC840760 @default.
- Q90026109 P356 CIZ628 @default.
- Q90026109 P698 31504303 @default.
- Q90026109 P1433 Q5133764 @default.
- Q90026109 P1476 "SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial" @default.
- Q90026109 P2093 "SD1000 Research Team" @default.
- Q90026109 P2093 "Shahin Merat" @default.
- Q90026109 P2507 Q90667223 @default.
- Q90026109 P31 Q13442814 @default.
- Q90026109 P356 "10.1093/CID/CIZ628" @default.
- Q90026109 P577 "2019-07-10T00:00:00Z" @default.
- Q90026109 P698 "31504303" @default.
- Q90026109 P921 Q2502747 @default.
- Q90026109 P921 Q42824827 @default.
- Q90026109 P921 Q5207712 @default.
- Q90026109 P921 Q6934595 @default.